AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03064867
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of R-ICE treatment:~Carboplatin: At a dose corresponding to an AUC = 5 based on Cockcroft-Gault calculation of GFR using adjusted body weight. Carboplatin is given IV on the Day 2 of RICE of each 21 day cycle
Trial: NCT03064867
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of R-ICE treatment:~Etoposide: 100 mg/m2by IV daily on 3 consecutive days (Days 1-3) of each 21-day cycle
Trial: NCT00031954
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00031954
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02380755
Drug: Clomiphene Citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg orally daily during 12 weeks
Trial: NCT00031954
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01816789
Drug: rFSH
RxNorm normalized name: rFSH-alpha
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01816789
Drug: buserelin
RxNorm normalized name: buserelin
DrugBank: Buserelin (DB06719)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01626339
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00347048
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02676830
Drug: K-312 100 mg
RxNorm normalized name: potassium gluconate
DrugBank: Potassium gluconate (DB13620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT00057226
Drug: Radafaxine
RxNorm normalized name: Radafaxine
DrugBank: Radafaxine (DB11790)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00844350
Drug: letrozole , oxytocin,hCG,clomiphene citrate
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02676830
Drug: K-312 100 ug C14 IV
RxNorm normalized name: potassium gluconate
DrugBank: Potassium gluconate (DB13620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: microtracer dose containing ≤37 kBq (1000 nCi) \[14C\] given as a 5-ml IV push over 2 minutes
Trial: NCT02502643
Drug: normal saline pleurodesis
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Make the patient supine position , Near the body of patient's chest tube is the injection site disinfection with the alcoholic Betadine and alcohol repeated three times.injected a solution of 30 cc of normal saline , and then injected into 20 cc air to the rubber chest tube , so that normal saline can completely into the chest, the injection site will cover with op site, use a rubber band to the rubber chest tube for hanging from the patient's body 40-60 cm high.Patients will reposition (left and right side)every 30 minutes in 2 hours
Trial: NCT00022555
Drug: bryostatin 1
RxNorm normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00022555
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02308241
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: self-administer ribavirin 1400 mg PO BID (total dose, 2800 mg/day)
Trial: NCT04047394
Drug: PEGylated recombinant candida urate oxidase
RxNorm normalized name: PEGylated recombinant candida urate oxidase
DrugBank: Pegadricase (DB15129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEGylated recombinant candida urate oxidase is a combination of 20kDa linear polyethylene glycol (PEG) linked to Candida utilis recombinant uricase by succinimide succinate
Trial: NCT01490229
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: os, 10 mg, once daily, 1 year
Trial: NCT01444196
Drug: Desloratadine
RxNorm normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Every day,per mouth,in the evening, for 14 +- 2 days.
Trial: NCT01490229
Drug: Nutraceuticals
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: os, 1 pill containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg, once daily, 1 year
Trial: NCT02048787
Drug: Buparlisib
RxNorm normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single dose of 50 mg buparlisib.
Trial: NCT00230997
Drug: Galantamine
RxNorm normalized name: Galantamine
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00140595
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02796105
Drug: Orgalutran
DrugBank: Ganirelix (DB06785)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02856594
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine
Trial: NCT00213590
Drug: cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The usual-exposure level was based on the mean area-under-the-concentration-time curve (AUC0-12h). In the usual-exposure group, the cyclosporine AUC0-12h target was 4.3 (3.5 to 4.8, range) mg•h/L and in the low-exposure group the target was 50% or 2.2 (2.0 to 2.6, range) mg•h/L. Ranges were asymmetrical for safety reasons, i.e., to prevent the occurrence of rejection in the low-exposure arm and nephrotoxicity in the usual-exposure arm.The AUC 0-12h was estimated using a Bayesian estimator and a three-point limited sampling strategy (0, 1, and 3 hours). A computer program was used to calculate the dose adjustment required to reach the therapeutic target. Doses were adjusted in increments of 25% to reach the target within 2 months. Cyclosporine AUC0-12h was determined every 2 months.
Trial: NCT00327145
Drug: valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00327145
Drug: hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00327145
Drug: amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01509391
Drug: keyhole-limpet hemocyanin
RxNorm normalized name: Keyhole limpet hemocyanin
DrugBank: Keyhole limpet hemocyanin (DB05299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration keyhole-limpet hemocyanin
Trial: NCT03050866
Drug: Cabazitaxel
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg/m2 q3w
Trial: NCT03385135
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg for 4 weeks then 600 mg for 4 weeks in the active group
Trial: NCT00736190
Drug: Tenofovir disoproxil fumarate
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300-mg tablet (marketed formulation) taken orally once daily
Trial: NCT00835796
Drug: Finasteride 5 mg tablets
RxNorm normalized name: Finasteride
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 5 mg, single dose fasting
Trial: NCT02095522
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine 1mg per day for one month
Trial: NCT02167594
Drug: Flortaucipir F18
RxNorm normalized name: Flortaucipir
DrugBank: Flortaucipir (DB15033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection, 370 megabecquerel (MBq) (10 mCi)
Trial: NCT01550302
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 37.5 mg of bupivacaine subcutaneously
Trial: NCT03032315
Drug: TAH Tablet (Telmisartan80/Amlodipine besylate10/Hydrochlorothiazide12.5)
RxNorm normalized name: Tahitian vanilla bean extract
DrugBank: Vanilla (DB10576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80.0 mg, Amlodipine besylate 13.87 mg (Amlodipine 10 mg), Hydrochlorothiazide 12.5 mg combination-drug would be administered orally once
Trial: NCT03032315
Drug: TWYNSTA(Telmisartan+Amlodipine besylate)
RxNorm normalized name: amlodipine / telmisartan Oral Tablet [Twynsta]
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TWYNSTA 2 Tab. 40/5mg(Telmisartan 40 mg, Amlodipine besylate 6.935 mg(Amlodipine 5 mg) would be administered orally once
Trial: NCT03032315
Drug: Hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dichlozid 1 Tab.(Hydrochlorothiazide 12.5 mg) would be administered orally once
Trial: NCT01218230
Drug: Intravitreal Pegaptanib
RxNorm normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravitreal pegaptanib, 0.3 mg, every 6 weeks for 3 injections and then PRN.
Trial: NCT02319044
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab monotherapy
Trial: NCT02319044
Drug: MEDI4736 + Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI4736 + Tremelimumab combination therapy
Trial: NCT03045016
Drug: Prazosin, ALPRESS® LP 2,5 et 5 mg
DrugBank: Prazosin (DB00457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will take Prazosin during 28 days ; there are two periods of treatment (escalation of doses):~* PERIOD 1 (Day 0 - Day 7): 1 tablet of ALPRESS LP 2.5 mg (Prazosin) at bedtime for 7 days~* PERIOD 2 (Day 8 - Day 27): 1 morning tablet of ALPRESS LP 5 mg (Prazosin) at bedtime for 21 days.
Trial: NCT02343627
Drug: Vehicle of test product
RxNorm normalized name: Dental Resources brand of Stannous Fluoride Dental Product
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vehicle of test product applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
Trial: NCT04147351
Drug: Atezolizumab Injection; bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: a PD-L1 inhibitor; anti-angiogenesis
Trial: NCT00362505
Drug: Clevudine
RxNorm normalized name: clevudine
DrugBank: Clevudine (DB06683)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04208698
Drug: CIN-102 Dose 1
RxNorm normalized name: CIN-QUIN
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deuterated domperidone (deudomperidone)
Trial: NCT04208698
Drug: CIN-102 Dose 2
RxNorm normalized name: CIN-QUIN
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deuterated domperidone (deudomperidone)
Trial: NCT00705653
Drug: PG-11047
RxNorm normalized name: PG
DrugBank: Benzylpenicillin (DB01053)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PG-11047 will be administered as a 60-minute intravenous infusion on days 1, 8 and 15 of each 28 day cycle. A treatment cycle will be defined as 4 weeks of therapy. The planned minimum treatment schedule is 2 cycles of PG-11047 treatment (8 weeks).
Trial: NCT00576927
Drug: Ramelteon
RxNorm normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects demonstrating low sleep efficiencies and prolonged sleep latencies, will be randomly assigned to continue to receive SHI accompanied by either placebo or Ramelteon (8 mg). Matching placebo will be obtained and the medication pre-packaged and ordered based on the randomization results.
Trial: NCT01608646
Drug: S-1 plus oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 14 with a single dose of oxaliplatin 130 mg/m2 will be administered as an 2-hour IV infusion following the morning dose of S-1 on Day 1. The combination therapy will be repeated every 3 weeks.
Trial: NCT00046228
Drug: abciximab placebo; reteplase placebo, abciximab, abciximab
DrugBank: Reteplase (DB00015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
Trial: NCT00014469
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00014469
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00014469
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04143880
Drug: Progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intramuscular injection intranasal administration
Trial: NCT00602342
Drug: Terbinafine
RxNorm normalized name: Terbinafine
DrugBank: Terbinafine (DB00857)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00965757
Drug: T-614
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-614 is administered twice daily in combination with methotrexate. The daily dose of T-614 is 25 mg for the first 4 weeks and 50 mg for subsequent weeks.
Trial: NCT03807440
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin
Trial: NCT03807440
Drug: Sodium Glucose Transporter 2 inhibitor
RxNorm normalized name: glucose / sodium chloride
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Glucose Transporter 2 inhibitor
Trial: NCT03807440
Drug: Dipeptidyl-peptidase 4 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dipeptidyl-peptidase 4 inhibitor
Trial: NCT00531999
Drug: Raltegravir then lopinavir/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: raltegravir 400mg twice daily for first 14 days of study lopinavir/ritonavir 400/100mg twice daily for last 14 days of study
Trial: NCT00531999
Drug: Lopinavir/ritonavir then raltegravir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lopinavir/ritonavir 400 mg twice daily for the first 14 days of the study raltegravir 400mg twice daily for the last 14 days of the study
Trial: NCT00029614
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00225173
Drug: Vinblastine
RxNorm normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinblastine 6 mg/m2 IV w 1,3,5,7,9,11
Trial: NCT00225173
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide2 60 mg/mg2 x 2 IV w 3, 7,11
Trial: NCT00225173
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine1 1.4 mg/m2 IV w 2,4,6,8,10,12 (cap @ 2mg)
Trial: NCT00225173
Drug: Bleomycin
RxNorm normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bleomycin 5 u/m2 IV w 2,4,6,8,10,12
Trial: NCT00225173
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1250 mg/m2 IV w 13,15,17,19
Trial: NCT00225173
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine 25 mg/m2 IV w 13,15,17,19
Trial: NCT00225173
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 40 mg/m2 PO qod w 1-10, taper
Trial: NCT02164812
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02164812
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03329950
Drug: CDX-1140
RxNorm normalized name: CDX
DrugBank: Cefadroxil (DB01140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CDX-1140 will be administered every 4 weeks in Parts 1, 2 and 4, and every 3 weeks in Part 3.
Trial: NCT03329950
Drug: CDX-301
RxNorm normalized name: CDX-301
DrugBank: CDX-301 (DB19293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDX-301 will be injected once a day for five days before Cycles 1 and 2.
Trial: NCT03329950
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: pembrolizumab will be administered every 3 weeks.
Trial: NCT00540826
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: in-label use
Trial: NCT00046228
Drug: Abciximab; reteplase; abciximab placebo; abciximab
DrugBank: Reteplase (DB00015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
Trial: NCT00046228
Drug: abciximab; reteplase placebo; abciximab placebo; abciximab
DrugBank: Reteplase (DB00015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
Trial: NCT00046228
Drug: abciximab placebo; reteplase placebo, abciximab, abciximab
DrugBank: Reteplase (DB00015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
Trial: NCT03807440
Drug: Glucagon-like peptide 1 agonist
RxNorm normalized name: Glucagon-like peptide II (2-glycine) (human)
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon-like peptide 1 agonist
Trial: NCT01747798
Drug: auranofin
RxNorm normalized name: Auranofin
DrugBank: Auranofin (DB00995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01217840
Drug: Drisdol (Ergocalciferol) Vitamin D2
RxNorm normalized name: ergocalciferol
DrugBank: Vitamin D (DB11094)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ergocalciferol 150,000 IU every 12 weeks for total of 24 weeks.
Trial: NCT04560725
Drug: 11C-Choline
RxNorm normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11C-choline (0.05-0.1mCi/kg) was injected intravenously one week before or after the \[68Ga\]P137 PET/CT examination, and imaging of the head and body cadres was performed 20 min after the injection using Philips Gemini TF16 or Siemens Biograph M-CT flow PET/CT
Trial: NCT00448825
Drug: Topiramate + Cognitive Behavioral Therapy
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate up to 300 mg per day
Trial: NCT01394419
Drug: N-acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine 150 mg/kg bolus over 15 min after induction of anesthesia, followed by an infusion of 150 mg/kg/day for 24 hrs
Trial: NCT01394419
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Equal volume of normal saline
Trial: NCT01572623
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Loading dose of Clopidogrel 600 mg versus 300 mg before carotid artery stenting
Trial: NCT01572623
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reloading dose of Atorvastatin (80 mg at 12 hours and 40 mg at 6-8 hours before carotid artery stenting) versus no reload.
Trial: NCT01466855
Drug: Intra-Ophthalmic Artery Topotecan Infusion
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topotecan via intra-ophthalmic artery delivery infused over 30 minutes on Day 1 of every 21-day cycle.
Trial: NCT00137748
Drug: CMV-Ig
RxNorm normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: CMV-Ig
Trial: NCT00662363
Drug: Lubiprostone
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 µg po BID given with meals for 6 days
Trial: NCT00662363
Drug: Senna
RxNorm normalized name: Senna
DrugBank: Senna leaf (DB15889)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tabs daily for 6 days
Trial: NCT00215956
Drug: topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative treatment: oral topotecan 5 days per week for up to 5 weeks
Trial: NCT01092754
Drug: Gadoversetamide
RxNorm normalized name: Gadoversetamide
DrugBank: Gadoversetamide (DB00538)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will receive a single dose of Optimark(0.1 mmol/kg)as a bolus thru a peripheral IV line at 1-2 mL/sec followed by a saline flush during their medically necessary MRI .
Trial: NCT00011076
Drug: Pirfenidone
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes